Haemocell (UK) on road to recovery
This article was originally published in Clinica
Executive Summary
Although Haemocell (UK) reported much improved revenues for the year ended August 31st, 1995, pretax losses increased to £2.52 million ($3.8 million) from £2.35 million in fiscal 1994. This is attributed to exceptional expenses of £404,000 resulting from actions to reduce costs. The increased turnover - from £212,000 in 1994 to £642,000 - reflects a recovery from the termination of Stryker's marketing deal for Haemocell's System 350 autologous blood transfusion system (see Clinica No 564/5, p 2). The UK company has established 37 distributors in 39 countries.